Seres Therapeutics, Inc.
NASDAQ: MCRB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard N. Kender
- Employees
- 103
- Headquarters
- Cambridge, United States
- IPO year
- 2015
- Market cap
- $65.9M
- Website
- https://www.serestherapeutics.com
Loading MCRB…
Loading profile data…Frequently asked questions about MCRB
What does Seres Therapeutics, Inc. (MCRB) do?
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile...
Where does MCRB trade?
Seres Therapeutics, Inc. (MCRB) trades on the NASDAQ Global Select.
What sector is MCRB in?
Seres Therapeutics, Inc. (MCRB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Seres Therapeutics, Inc.?
Richard N. Kender is the chief executive officer of Seres Therapeutics, Inc. (MCRB).
Where is Seres Therapeutics, Inc. headquartered?
Seres Therapeutics, Inc. is headquartered in United States.
Does MCRB pay a dividend?
Seres Therapeutics, Inc. (MCRB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MCRB go public?
Seres Therapeutics, Inc. (MCRB) completed its initial public offering in 2015.